跳至主要内容
临床试验/NCT00812214
NCT00812214已完成4 期

Treatment of Insomnia in Migraineurs With Eszopiclone (Lunesta™) and Its Effect on Sleep Time, Headache Frequency, and Daytime Functioning: a Randomized, Double-blind, Placebo-controlled, Parallel-group Pilot Study

MedVadis Research Corporation0 个研究点目标入组 113 人开始时间: 2007年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
113
主要终点
Total Sleep Time

研究概览

简要总结

It is hypothesized that treating insomnia in migraineurs, many of whom also have tension headaches, prolongs total sleep time to the extent that it decreases overall headache frequency. Chronic headache sufferers also feel more tired during the day, undoubtedly affecting daytime functioning, which is hypothesized to improve as well with prolonged total sleep time.

详细描述

The objective of the study is to determine the effect of prolonging total sleep time in migraineurs with insomnia on overall headache frequency, daytime alertness, fatigue, and functioning. The prolongation of total sleep time is accomplished by bedtime administration of 3 mg eszopiclone (Lunesta™), compared with placebo through a parallel-group design.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Eszopiclone (Lunesta) 3mg

Experimental

Participants with IHS-II migraine with and/or without aura and with DSM-IV primary insomnia. They were treated for 6 weeks with 3mg eszopiclone, followed by a 2-week runout period. Participants came in for five visits: a screening visit, a randomization visit, a compliance visit, an end-treatment visit, and an exit/early termination visit.

干预措施: eszopiclone (Drug)

Placebo

Placebo Comparator

Participants with IHS-II migraine with and/or without aura and with DSM-IV primary insomnia. They were treated for 6 weeks with placebo, followed by a 2-week runout period. Participants came in for five visits: a screening visit, a randomization visit, a compliance visit, an end-treatment visit, and an exit/early termination visit.

干预措施: placebo (Drug)

结局指标

主要结局

Total Sleep Time

时间窗: Baseline, 6 weeks

Participants were asked to record an estimated total time asleep on a daily basis. Nightly estimates were averaged over a 2 week period for baseline and 6 week period so that the total sleep time represents the average total time asleep each night.

次要结局

  • Headache Duration(Baseline, 6 weeks)
  • Nighttime Awakenings(Measured every two weeks (1&2, 3&4, 5&6))
  • Daytime Fatigue(Measured every two weeks (1&2, 3&4, 5&6))
  • Headache Intensity(Baseline, 6 weeks)
  • Quality of Sleep(Baseline, 6 weeks)
  • Headache Frequency(Baseline, 6 weeks)

研究者

发起方
MedVadis Research Corporation
申办方类型
Industry
责任方
Sponsor

相似试验